HK82597A - Use of a tetrahydrocarbazolone derivative for the manufacture of medicaments - Google Patents

Use of a tetrahydrocarbazolone derivative for the manufacture of medicaments Download PDF

Info

Publication number
HK82597A
HK82597A HK82597A HK82597A HK82597A HK 82597 A HK82597 A HK 82597A HK 82597 A HK82597 A HK 82597A HK 82597 A HK82597 A HK 82597A HK 82597 A HK82597 A HK 82597A
Authority
HK
Hong Kong
Prior art keywords
sub
sup
compound
methyl
active ingredient
Prior art date
Application number
HK82597A
Other languages
English (en)
French (fr)
Inventor
Brian Tyers Michael
Harold Coates Ian
Cedric Humber David
Blanch Ewan George
Angus Bell James
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40347948&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK82597(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of HK82597A publication Critical patent/HK82597A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Claims (5)

  1. Verwendung von 1,2,3,9-Tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-on oder eines physiologisch annehmbaren Salzes oder Hydrats davon, zur Herstellung eines Arzneimittels zur Linderung von Übelkeit und Erbrechen.
  2. Verwendung gemaß Anspruch 1, worin das 1,2,3,9-Tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-on in Form eines Hydrochlorids vorliegt.
  3. Verwendung gemäß Anspruch 1, worin das 1,2,3,9-Tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-on in Form seines Hydrochlorid-Dihydrats vorliegt.
  4. Verwendung gemäß einem der Ansprüche 1 bis 3 zur Herstellung eines Arzneimittels, das in Kombination mit einem therapeutischen Antikrebsmittel zu verwenden ist.
  5. Verwendung gemäß Anspruch 4, worin das therapeutische Antikrebsmittel Cisplatin ist.
HK82597A 1985-06-25 1997-06-19 Use of a tetrahydrocarbazolone derivative for the manufacture of medicaments HK82597A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB858516083A GB8516083D0 (en) 1985-06-25 1985-06-25 Heterocyclic compounds
GB868628474A GB8628474D0 (en) 1985-06-25 1986-11-28 Pharmaceutical compositions

Publications (1)

Publication Number Publication Date
HK82597A true HK82597A (en) 1997-06-27

Family

ID=40347948

Family Applications (1)

Application Number Title Priority Date Filing Date
HK82597A HK82597A (en) 1985-06-25 1997-06-19 Use of a tetrahydrocarbazolone derivative for the manufacture of medicaments

Country Status (22)

Country Link
US (2) US4753789A (de)
EP (2) EP0226266B1 (de)
JP (2) JPS6253920A (de)
AT (2) ATE134510T1 (de)
AU (2) AU609028B2 (de)
BE (1) BE1002249A4 (de)
CA (1) CA1296637C (de)
CH (1) CH672068A5 (de)
CY (1) CY2000A (de)
DE (2) DE3650488T2 (de)
DK (1) DK624687A (de)
FR (1) FR2613934B1 (de)
GB (3) GB8516083D0 (de)
HK (1) HK82597A (de)
IE (1) IE60908B1 (de)
IL (1) IL84638A (de)
IT (1) IT1211937B (de)
NL (1) NL8702853A (de)
NZ (1) NZ222743A (de)
SE (1) SE8704747L (de)
SG (1) SG43311A1 (de)
ZA (1) ZA878927B (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0385517B1 (de) * 1985-03-14 1993-04-14 BEECHAM GROUP plc Arzneimittel zur Behandlung von Erbrechen
US5578628A (en) * 1985-06-25 1996-11-26 Glaxo Group Limited Medicaments for the treatment of nausea and vomiting
GB8516083D0 (en) * 1985-06-25 1985-07-31 Glaxo Group Ltd Heterocyclic compounds
GB8627909D0 (en) * 1986-11-21 1986-12-31 Glaxo Group Ltd Medicaments
US5330982A (en) * 1986-12-17 1994-07-19 Glaxo Group Limited Pharmaceutical composition containing a 5-HT receptor antagonist and an H+ K+ Atpase inhibitor and a method of treating gastrointestingal disorders therewith
IE60991B1 (en) * 1986-12-17 1994-09-07 Glaxo Group Ltd Use of ketone derivatives in the treatment of cognitive disorders
GB8630080D0 (en) * 1986-12-17 1987-01-28 Glaxo Group Ltd Medicaments
GB8630071D0 (en) * 1986-12-17 1987-01-28 Glaxo Group Ltd Medicaments
GB8630079D0 (en) * 1986-12-17 1987-01-28 Glaxo Group Ltd Medicaments
JPH0754759B2 (ja) * 1987-04-27 1995-06-07 日本電信電話株式会社 プラズマ処理方法および装置並びにプラズマ処理装置用モード変換器
US4943428A (en) * 1987-07-10 1990-07-24 Wright State University Stimulation of serotonin-1A receptors in mammals to alleviate motion sickness and emesis induced by chemical agents
DE3822792C2 (de) * 1987-07-11 1997-11-27 Sandoz Ag Neue Verwendung von 5HT¶3¶-Antagonisten
GB8805269D0 (en) * 1988-03-04 1988-04-07 Glaxo Group Ltd Medicaments
GB8806224D0 (en) * 1988-03-16 1988-04-13 Johnson Matthey Plc Platinum chemotherapeutic product
GB8816187D0 (en) * 1988-07-07 1988-08-10 Glaxo Group Ltd Medicaments
US5047246A (en) * 1988-09-09 1991-09-10 Bristol-Myers Company Direct compression cyclophosphamide tablet
AU627221B2 (en) * 1988-09-27 1992-08-20 Fujisawa Pharmaceutical Co., Ltd. Pyridoindole derivatives and processes for preparation thereof
GB8904182D0 (en) * 1989-02-23 1989-04-05 Glaxo Canada Pharmaceutical compositions
US5039528A (en) * 1989-12-11 1991-08-13 Olney John W EAA antagonists as anti-emetic drugs
US4971651A (en) * 1990-02-05 1990-11-20 Hitachi, Ltd. Microwave plasma processing method and apparatus
CA2112488A1 (en) * 1991-06-26 1993-01-07 James W. Young Method and compositions for treating emesis, nausea and other disorders using optically pure s(-) ondansetron
WO1993000074A1 (en) * 1991-06-26 1993-01-07 Sepracor, Inc. Method and compositions for treating emesis, nausea and other disorders using optically pure r(+) ondansetron
ES2149767T5 (es) * 1991-09-20 2005-06-16 Glaxo Group Limited Nuevo uso medico para antagonistas de taquiquininas.
EP0688216A1 (de) * 1993-03-08 1995-12-27 Fujisawa Pharmaceutical Co., Ltd. Medikament zur behandlung und prävention von zerebrovaskulären erkrankungen
GB9310756D0 (en) * 1993-05-25 1993-07-14 Glaxo Lab Sa Compositions
GB9423511D0 (en) * 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
GB9423588D0 (en) * 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
WO2000051582A2 (en) 1999-03-01 2000-09-08 Sepracor Inc. Methods for treating apnea and apnea disorders using optically pure r(+)ondansetron
RU2162695C1 (ru) * 2000-07-14 2001-02-10 ООО с иностранными инвестициями "Редди-Биомед лимитед" Способ получения ондансетрона гидрохлорида дигидрата, субстанция и фармацевтический препарат
KR100434390B1 (ko) * 2001-04-20 2004-06-04 안국약품 주식회사 1,2,3,9-테트라히드로-9-메틸-3-[(2-메틸-1ｈ-이미다졸-1-일)메틸]-4ｈ-카바졸-4-온을 유효성분으로 하는 비강분무용조성물
JP5690461B2 (ja) * 2002-11-15 2015-03-25 ヘルシン ヘルスケア ソシエテ アノニム 化学療法誘導嘔吐を治療するためのパロノセトロン
ES2285407T3 (es) * 2003-01-13 2007-11-16 Dynogen Pharmaceuticals Inc. Metodo para el tratamiento de nauseas, vomitos, arcadas o cualquiera de sus combinaciones.
US8598219B2 (en) 2003-01-30 2013-12-03 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
JO2735B1 (en) * 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formulations of palonosetron
TWI355936B (en) * 2003-02-18 2012-01-11 Helsinn Healthcare Sa Uses of palonosetron hydrochloride
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
US20060167072A1 (en) * 2004-01-30 2006-07-27 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
US7288660B2 (en) * 2004-05-07 2007-10-30 Taro Pharmaceutical Industries Limited Process for preparing ondansetron hydrochloride dihydrate having a defined particle size
US20060068010A1 (en) * 2004-09-30 2006-03-30 Stephen Turner Method for improving the bioavailability of orally delivered therapeutics
WO2006105117A2 (en) * 2005-03-28 2006-10-05 Dynogen Pharmaceuticals, Inc. Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
EA016455B1 (ru) * 2006-10-24 2012-05-30 Хелсинн Хелткэр С.А. Мягкие капсулы, содержащие палоносетрона гидрохлорид, имеющие улучшенную стабильность и биологическую доступность
JP2010050046A (ja) 2008-08-25 2010-03-04 Hitachi High-Technologies Corp プラズマ処理装置
CA2784587A1 (en) 2009-12-28 2011-07-28 Monosol Rx, Llc Orally administrable film dosage forms containing ondansetron
MX342993B (es) 2013-04-25 2016-10-13 Inst Mexicano Del Petróleo Proceso de obtencion de copolimeros aleatorios derivados del acido itaconico y/o sus isomeros y alquenil sulfonatos de sodio y uso del producto obtenido.
EP3589369A4 (de) * 2017-01-09 2020-03-18 DAS-MG, Inc. Verwendung und zusammensetzung zur behandlung von myasthenia gravis und anderen myasthenischen syndromen

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0040489A1 (de) * 1980-05-17 1981-11-25 FISONS plc Mischungen, Salze, Packungen und pharmazeutische Zusammensetzungen mit Gehalt an 5-(2-Hydroxypropoxy)-4-oxo-8-propyl-4H-1-benzopyran-2-carbonsäure oder einem Derivat derselben und einem H2-Rezeptoren antagonisierenden Antihistamin
BE894285A (fr) * 1981-09-04 1983-03-02 Glaxo Group Ltd Composition pharmaceutique contenant un medicament anti-inflammatoire et de la ranitidine ou un sel de ce compose
DE3445377A1 (de) * 1983-12-23 1985-07-04 Sandoz-Patent-GmbH, 7850 Lörrach Carbocylische und heterocyclische carbonsaeureester und -amide von ueberbrueckten und nicht ueberbrueckten cyclischen stickstoffhaltigen aminen oder alkoholen
US4695578A (en) * 1984-01-25 1987-09-22 Glaxo Group Limited 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances
PH22672A (en) * 1984-01-25 1988-11-14 Glaxo Group Ltd Imidazolylmethyltetrahydrocarbazolone derivatives, composition and method of use thereof
AU583343B2 (en) * 1985-01-23 1989-04-27 Glaxo Group Limited Heterocyclic compounds
EP0385517B1 (de) * 1985-03-14 1993-04-14 BEECHAM GROUP plc Arzneimittel zur Behandlung von Erbrechen
GB8516083D0 (en) * 1985-06-25 1985-07-31 Glaxo Group Ltd Heterocyclic compounds
GB8630079D0 (en) * 1986-12-17 1987-01-28 Glaxo Group Ltd Medicaments

Also Published As

Publication number Publication date
GB2200046A (en) 1988-07-27
SE8704747L (sv) 1988-05-29
GB2200046B (en) 1990-09-26
FR2613934B1 (fr) 1993-07-09
JPH0324447B2 (de) 1991-04-03
IT1211937B (it) 1989-11-08
DK624687A (da) 1988-05-29
CH672068A5 (de) 1989-10-31
SG43311A1 (en) 1997-10-17
CA1296637C (en) 1992-03-03
DE3740351A1 (de) 1988-06-09
FR2613934A1 (fr) 1988-10-21
GB8628474D0 (en) 1987-01-07
ATA312587A (de) 1992-05-15
NL8702853A (nl) 1988-06-16
DK624687D0 (da) 1987-11-27
BE1002249A4 (fr) 1990-11-06
EP0226266A2 (de) 1987-06-24
GB8516083D0 (en) 1985-07-31
EP0226266B1 (de) 1996-02-28
NZ222743A (en) 1991-09-25
SE8704747D0 (sv) 1987-11-27
EP0431443A2 (de) 1991-06-12
US4753789A (en) 1988-06-28
CY2000A (en) 1997-12-05
JPS63198623A (ja) 1988-08-17
AU6703786A (en) 1988-06-30
AT395374B (de) 1992-12-10
JPS6253920A (ja) 1987-03-09
IE60908B1 (en) 1994-08-24
DE3650488T2 (de) 1996-09-05
ZA878927B (en) 1988-10-26
ATE134510T1 (de) 1996-03-15
US4929632A (en) 1990-05-29
GB8727836D0 (en) 1987-12-31
IE873230L (en) 1988-05-28
IT8748643A0 (it) 1987-11-27
EP0431443A3 (en) 1991-09-18
AU8191487A (en) 1988-06-02
DE3650488D1 (de) 1996-04-04
IL84638A (en) 1992-05-25
AU609028B2 (en) 1991-04-26
EP0226266A3 (en) 1990-01-24
AU616386B2 (en) 1991-10-31

Similar Documents

Publication Publication Date Title
EP0226266B1 (de) Verwendung eines Tetrahydrocarbazolonderivates zur Herstellung von Arzneimitteln
US5578628A (en) Medicaments for the treatment of nausea and vomiting
EP0216555B1 (de) Verwendung von Dioxopiperidin-Derivaten zur Behandlung von Anxietas, zur Herabsetzung von chronischen abnormal hohen Gehirn-Spiegeln Serotonins oder 5-Hydroxy-Indolessigsäure und zur Behandlung von bakteriellen oder viralen Infektionen
EP0615751B1 (de) Verwendung von Tachykinin-Antagonisten zur Behandlung von Erbrechen
JPH0555484B2 (de)
EP0559297B1 (de) Verwendung von heterozyklischen Derivaten zur Herstellung von Arzneimitteln
US4835173A (en) Method of medical treatment
US5098909A (en) 5-ht3 receptor antagonists for treatment of cough and bronchoconstriction
US5240954A (en) Medicaments
US3885035A (en) Method for treating arrhythmia by using 1,4-bis(4 quinazolinyl) piperazines
EP0552205B1 (de) Neue medizinische anwendung eines gewissen indolderivates und dieses enthaltende pharmazeutische zubereitung
US5482716A (en) Medicaments
JP2834175B2 (ja) 医 薬
CA2100777C (en) Pharmaceutical composition containing granisetron and dexamethasone
EP0411900A2 (de) Arzneimittel zur Behandlung von Bulimie
EP0269452A2 (de) Anwendung von Keton-Derivaten zur Herstellung von Arzneimitteln
US5221687A (en) Medicaments
US5276050A (en) Medicaments
JPH0827000A (ja) 悪阻による諸症状の予防または治療薬
JPH10152442A (ja) 抗肥満剤
JPH0827001A (ja) 術後嘔吐の予防または治療薬
JPH01250319A (ja) 医薬

Legal Events

Date Code Title Description
PF Patent in force
PE Patent expired

Effective date: 20060623